News Hub | News Direct

ALLIED CORP SIGNS MAJOR SUPPLY AGREEMENT WITH US MULTI STATE OPERATOR (MSO) AND SALES AGREE-MENT FOR ALLIED’S CBD BRANDS

Allied Corp

Allied Corp. ("Allied" or the “Company”) ( OTCQB: ALID ) is pleased to announce the signing of what we believe to be another major supply agreement for the 2022 calendar year. Allied will be only providing cannabis flower after the Colombian government allows it and will provide supply only to countries where it is legal to sell into (for example, the United States only allows for THC levels to be less than 0.3%). In addition to the quantities contemplated in the October 07, 2021 press release, on October 17, 2021, Allied signed another supply contract with a US Multi State Operator for 12,000 kilograms of dried cannabis flower for the 2022 calendar year. This product will be supplied starting in January 2022 and will be the beginning of another monthly recurring supply contract. In addition to this, Allied has also signed a purchase order for its branded CBD products in the United States. Through this agreement, Allied products will be sent to retail stores within the states of California and Nevada. These products include: Tactical Relief™ Liberty CBD Tincture Tactical Relief™ Rapid Recovery Roll on Oil Tactical Relief™ Battle Balm Tactical Relief™ Fizzy Tabs Tactical Relief™ Tactical Hydration Tactical Relief™ Quick Hit Gummies Equilibrium Bio™ CBD Tincture Equilibrium Bio™ Rapid Recovery Roll on Oil Equilibrium Bio™ Athletic Rub Equilibrium Bio™ Fizzy Tabs Equilibrium Bio™ Hydration Drinks Equilibrium Bio™ Gummies MaXXa™ Skin Structure MaXXa™ Eye Recover Maxxa™ Glossy Lip Recover MaXXa™ Skin Designer MaXXa™ Vitamin Absolute MaXXa™ Absolute Recover Under the 2018 Farm Bill, the United States legalized the ability to sell CBD based natural health products. The THC threshold limit is set at 0.3%THC. All of Allied’s products are currently within the legal thresholds and within compliance of the national laws in the United States. “We are ready to provide large volumes of high quality cannabis to the international marketplace. With several supply contracts signed for the 2022 calendar year, we are ready to start shipping when Colombia allows. Allied harvests on a weekly basis and by nature of this we believe that we will be able to provide rolling supply that is harvested fresh every week. In addition to this, we are offering attractive terms to approved off take partners to offer what we believe to be a de-risked pricing structure to the sales cycle.” said Mr. Calum Hughes, CEO and Chairman of Allied Corp. About Allied Corp. - https://allied.health/ Allied Corp. is an international cannabis company with its main production center in Colombia and is one of the few companies that has exported from Colombia internationally. In preparation for the possible legalization of cannabis by the US Federal Government, Allied also has the option to purchase a US cannabis license in the US (Nevada) exercisable if such were to happen. In addition to this, Allied has three CBD-brands to market with products selling in the United States. Lastly, Allied has both Cannabinoid and psilocybin products in the pharmaceutical development track seeking pharma drug indications for depression, anxiety and PTSD. Investor Relations:ir@allied.health1-877-255-4337 Forward-Looking Statements: This press release contains “forward-looking information” within the meaning of applicable securities laws in Canada or the United States ( “forward-looking information”). Forward-looking information may relate to the Company’s future outlook and anticipated events, plans or results, and may include information regarding the Company’s objectives, goals, strategies, future revenue or performance and capital expenditures, and other information that is not historical information. Forward-looking information can often be identified by the use of terminology such as “believe,” “anticipate,” “plan,” “expect,” “pending,” “in process,” “intend,” “estimate,” “project,” “may,” “will,” “should,” “would,” “could,” “can,” the negatives thereof, variations thereon and similar expressions. The forward-looking information contained in this press release is based on the Company’s opinions, estimates and assumptions in light of management’s experience and perception of historical trends, current conditions and expected future developments, as well as other factors that management currently believes are appropriate and reasonable in the circumstances. Forward looking statements in this press release include the following: that Allied is leveraging the conditions in its Colombia grow operation and future Kelowna location to support its Research and Development efforts; that Allied is making important strides forward to position itself as a leader in the medical cannabis space, that Allied intends to make a series of proposed trademark and other intellectual property protection filings, as part of the Company’s Intellectual Property and Pharma Development (IP&PD) Strategy, statements respecting the joint development, manufacturing, and the introduction of TACTICAL RELIEF™ branded products. There can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct. Risk factors that could cause actual results to differ materially from forward-looking information in this release include: the Company’s exposure to legal and regulatory risk; the effect of the legalization of adult-use cannabis in Canada and Colombia on the medical cannabis industry is unknown and may significantly and negatively affect the Company’s medical cannabis business; that the medical benefits, viability, safety, efficacy, dosing and social acceptance of cannabis are not as currently expected; that adverse changes or developments affecting the Company’s main or planned facilities may have an adverse effect on the Company; that the medical cannabis industry and market may not continue to exist or develop as anticipated or the Company may not be able to succeed in this market; risks related to completion of the greenhouse construction in Colombia, risks related to market competition; risks related to the proposed adult-use cannabis industry and market in Canada and Colombia including the Company’s ability to enter into or compete in such markets; that the Company has a limited operating history and a history of net losses and that it may not achieve or maintain profitability in the future; risks related to the Company’s current or proposed international operations; risks related to future third party strategic alliances or the expansion of currently existing relationships with third parties; that the Company may not be able to successfully identify and execute future acquisitions or dispositions or successfully manage the impacts of such transactions on its operations; risks inherent to the operation of an agricultural business; that the Company may be unable to attract, develop and retain key personnel; risks resulting from significant interruptions to the Company’s access to certain key inputs such as raw materials, electricity, water and other utilities; that the Company may be unable to transport its cannabis products to patients in a safe and efficient manner; risks related to recalls of the Company’s cannabis products or product liability or regulatory claims or actions involving the Company’s cannabis products; risks related to the Company’s reliance on pharmaceutical distributors; that the Company, or the cannabis industry more generally, may receive unfavorable publicity or become subject to negative consumer or investor perception; that certain events or developments in the cannabis industry more generally may impact the Company’s reputation or its relationships with customers or suppliers; that the Company may not be able to obtain adequate insurance coverage in respect of the risks that it faces, that the premiums for such insurance may not continue to be commercially justifiable or that there may be coverage limitations and other exclusions which may result in such insurance not being sufficient; that the Company may become subject to liability arising from fraudulent or illegal activity by its employees, contractors, consultants and others; that the Company may experience breaches of security at its facilities or losses as a result of the theft of its products; risks related to the Company’s information technology systems; that the Company may be unable to sustain its revenue growth and development; that the Company may be unable to expand its operations quickly enough to meet demand or manage its operations beyond their current scale; that the Company may be unable to secure adequate or reliable sources of necessary funding; risks related to, or associated with, the Company’s exposure to reporting requirements; risks related to conflicts of interest; risks related to fluctuations in foreign currency exchange rates; risks related to the Company’s potential exposure to greater-than-anticipated tax liabilities; risks related to the protection and enforcement of the Company’s intellectual property rights, or the intellectual property that it licenses from others; that the Company may become subject to allegations that it or its licensors are in violation of the intellectual property rights of third parties; that the Company may not realize the full benefit of the clinical trials or studies that it participates in; that the Company may not realize the full benefit of its licenses if the licensed material has less market appeal than expected and the licenses may not be profitable; as well as any other risks that may be further described in and the risk factors discussed in the Company's continuous disclosure including its Management's Discussion and Analysis sections in its Quarterly Reports on Form 10-Q, Annual Reports on Form 10-K and Current Reports on Form 8-K filed under the Company's profile at www.sec.gov. Although management has attempted to identify important risk factors that could cause actual results to differ materially from those contained in the forward-looking information in this presentation, there may be other risk factors not presently known to the Company or that the Company presently believes are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information in this presentation. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers and viewers should not place undue reliance on forward-looking information, which speaks only as of the date made. The forward-looking information contained in this release represents the Company’s expectations as of the date of this release or the date indicated, regardless of the time of delivery of the presentation. The Company disclaims any intention, obligation or undertaking to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required under applicable securities laws. Contact Details Allied Corp Investor Relations +1 877-255-4337 ir@allied.health Company Website https://allied.health/

October 19, 2021 05:55 AM Pacific Daylight Time

Pediatric Lyme Disease—'An Epidemic Within a Pandemic!’—to be Focus of Free Webinar Hosted by Quidel Corporation Oct. 21

Quidel Corporation

Among the many health challenges facing children is the very real threat of contracting Lyme disease as nearly 30% of the estimated 476,000 people in the U.S. each year who are diagnosed and treated for this disease are ages 0-19. In response to this troubling fact, an important webinar focused on how Lyme disease affects the pediatric population will be held on Thursday, Oct. 21. The free webinar—titled Pediatric Lyme Disease: “An Epidemic Within a Pandemic!”—is part of an ongoing series hosted by Quidel, the California-based diagnostic health care manufacturer known for successfully developing rapid diagnostic health solutions. The program is being held in collaboration with the Global Lyme Alliance. Registration is now available at http://education.quidel.com/frontmatter/2591/1/Ped-Lyme. Conducting the webinar will be Robert A. Dracker, M.D., medical director at Summerwood Pediatrics and Infusacare Medical Services in Liverpool, New York. Dr. Dracker currently serves as chair of the heart, lung and cancer committee for the Medical Society of New York State and is a board member of the Office of Professional Conduct for the New York State Department of Health. Since 2014 he has been a member of the Pediatric Advisory Committee of the FDA and served as chairman of the committee from 2018-2019. The Oct. 21 webinar will discuss how Lyme disease presents in children (often flu-like symptoms including fever, chills, malaise and headache), how it progresses and tick-exposure management. Also discussed will be how to test for Lyme disease, including the innovative Sofia® 2 Lyme FIA test. This revolutionary test provides the patient and physician with indicative results within 15 minutes, as opposed to days, which has historically been the norm (and during which time organisms can spread and become systemic). It can be performed in the privacy of a doctor’s office or local clinic, and it is the only test that can get results from a simple finger prick of blood. “Children, for the most part, are more engaged on a regular basis than are adults in outside activities, which is why being on guard and testing for Lyme disease is so important,” said Dr. Dracker. “If left untreated, the bacteria that cause Lyme disease can attack many systems of a child’s body, including the skin, heart, nerves and joints. While each child is different, to a tick they are all the same and are all just waiting to be bitten. Parents need to be vigilant, and physicians need to be attuned so children can enjoy the wonderment of being a child while remaining safe and smart.” Among those expected to attend the webinar are pediatricians, representatives of physician office laboratories, urgent care centers, and any other allied health professionals or health care researchers interested in hearing the latest regarding the prevalence of Lyme disease in children. The free, Oct. 21, webinar will take place from noon to 1 p.m. (EDT). To register, visit http://education.quidel.com/frontmatter/2591/1/Ped-Lyme. About Quidel Corporation Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of diagnostic solutions at the point of care, delivering a continuum of rapid testing technologies that further improve the quality of health care throughout the globe. An innovator for over 40 years in the medical device industry, Quidel pioneered the first FDA-cleared point-of-care test for influenza in 1999 and was the first to market a rapid SARS-CoV-2 antigen test in the U.S. Under trusted brand names, Sofia®, Solana®, Lyra®, Triage® and QuickVue®, Quidel’s comprehensive product portfolio includes tests for a wide range of infectious diseases, cardiac and autoimmune biomarkers, as well as a host of products to detect COVID-19. With products made in America, Quidel’s mission is to provide patients with immediate and frequent access to highly accurate, affordable testing for the good of our families, our communities and the world. For more information about Quidel, visit quidel.com. Contact Details Jim Yeager +1 818-264-6812 jim@breakwhitelight.com Company Website http://Quidel.com

October 18, 2021 02:56 PM Eastern Daylight Time

Ultrahuman hires former KKR exec ahead of expansion drive

Ultrahuman

Ultrahuman, the rapidly growing metabolic fitness platform, has today appointed its first chief business officer, installing Bhuvan Srinivasan in the leadership team. This appointment comes hot on the heels of the recent $17.5m funding round as Ultrahuman aims to help over a billion people in the world improve their metabolic fitness. Bhuvan has spent over 14 years in consultancy and private equity before joining Ultrahuman. He was most recently a Director in KKR's India team where he led multiple investments in pharma, hospitals, waste management, tech and education. His key focus was to drive transformation, turbocharge growth, hire senior management, lead M&A transactions and achieve successful funding rounds and exits for their portfolio. Prior to joining KKR, Bhuvan was with Bain Capital. Prior to that he was with Bain & Company in Singapore working with businesses in Southeast Asia and across the Middle East. He holds an MBA with honors from The Wharton School of the University of Pennsylvania. Having read his undergrad and masters in Biomedical Engineering from the Johns Hopkins University, Bhuvan began his career as a research scientist working on continuous glucose monitoring at Medtronic Diabetes in Los Angeles. On his appointment to chief business officer at Ultrahuman, Bhuvan Srinivasan commented: “Life has come full circle for me in joining Ultrahuman. I began my career as a research scientist for glucose sensors for diabetes. Since then, I have benefitted from working closely with a range of businesses and people, skills that I will be able to utilise in driving the future trajectory of Ultrahuman as it scales globally. Research over the last 15 years has shown that good glucose control is important for preventing other diseases as well, including cardiovascular disease, Alzheimer’s and even cancer. I have been an avid supporter of the business over the years and am thrilled to be joining this amazing group of people who are focussed on making a huge impact.” Ultrahuman was started by Mohit Kumar and Vatsal Singhal who were also co-founders at Runnr that later merged with Zomato. Mohit is an avid cyclist, biohacker and Brazilian Jiu-Jitsu enthusiast. Vatsal is a cross fit enthusiast and biohacker. Mohit was training at one of the largest MMA Camps in the world (Tiger Muay Thai). There he observed athletes train smartly via usage of data, recovery tools and protocols. He got together with Vatsal and they came up with a vision for Ultrahuman where they can make the journey of fitness for people more personalised and impactful. “We are navigating our scale up journey and having people like Bhuvan will certainly bolster our efforts. His appointment is part of the next phase of growth and his experience in building businesses will provide the perspective and guidance Ultrahuman requires as we charter the course” said Ultrahuman Founder and CEO Mohit Kumar. The metabolic health crisis is unarguably one of the largest healthcare crises that exists today. Over a billion people in the world suffer from a metabolic health disorder which contributes to almost 85% of all chronic diseases in the world. By helping people understand how food and exercise affects their metabolic health, people would be able to make informed choices about what they eat and their activity levels. The approach is a geography / diet agnostic way to help people eat and exercise better. The Ultrahuman Cyborg wearable helps people optimize their exercise and nutrition based on glucose biomarkers. Launched in June 2021, Ultrahuman has already amassed tens of thousands of people on a waitlist whilst users rave about their experience on Twitter after using the wearable. An important biomarker like glucose can be very revealing about how a particular food item affects the user’s metabolic health by measuring the glucose response. This response is unique to an individual and it depends on various factors like their microbiome diversity, stress levels, time of the day, food ingredient quality etc. About Ultrahuman Ultrahuman is headquartered in the US and India. It is the world's most advanced metabolic fitness platform. It helps people create long-term habits and changes via instant nudges and deep health insights instead of diets and strict exercise routines. For more information and updates on Ultrahuman, please visit ultrahuman.com Contact Details Ultrahuman Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://ultrahuman.com/

October 18, 2021 08:00 AM Pacific Daylight Time

Image

The U.S. Chamber Discover & Deliver Initiative Spotlights Medical Innovation Happening across Main Street America

YourUpdateTV

You may be surprised to learn that cutting edge medical innovation is happening right now in your own community—from coronavirus to cancer, America’s innovation community is mobilized like never before. Across main street America, businesses of all sizes, the public sector, and academic institutions are making remarkable progress in developing the next generation of breakthrough treatments, vaccines, and diagnostics we need. The results are clear—working together we achieve more. That’s why the U.S. Chamber Discover & Deliver initiative is spotlighting the role of business in bringing science to life and delivering it to humanity. It’s the story of a nationwide, cross-industry effort that involves our brightest scientific minds, the most innovative companies, and the nation’s leading universities—all working together toward the common goal of making a healthier global community. The scope is as impressive as the speed. Scientists are conducting more than 140,000 clinical trials across the United States, in all 50 states, from big cities to small towns. This search for new medical solutions and cures also supports hometown economies by creating good jobs and driving growth. Discover & Deliver is conducting outreach in communities across the United States to engage local leaders, share the latest information, and provide a “peek inside the pipeline” to shed light on what science can tackle next. To help illustrate this story, the U.S. Chamber developed an interactive map, to show what’s happening across our country—in communities large and small—as innovation works to identify the solutions needed to fight disease. Visit www.USChamber.com for the latest resources and insights into how business is stepping up in extraordinary ways to solve our biggest challenges. About YourUpdateTV: YourUpdateTV is a social media video portal for organizations to share their content.. It includes separate channels for Health and Wellness, Lifestyle, Media and Entertainment, Money and Finance, Social Responsibility, Sports and Technology. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

October 15, 2021 03:40 PM Eastern Daylight Time

Living With Narcolepsy: Symptoms and Misconceptions

YourUpdateTV

Confusion, stereotypes, and stigma about the sleep disorder narcolepsy persist to this day. This can lead to a long time to diagnosis and prevent people who think they have narcolepsy from reaching out to a healthcare professional to learn more. So, what is narcolepsy? Narcolepsy is a rare, chronic, debilitating neurological disorder that affects the way the brain controls sleep-wake cycles. 1,2 Narcolepsy affects approximately 165,000 Americans, with one of its main symptoms being excessive daytime sleepiness, or the inability to stay awake and alert during the day. 1 Other symptoms may include cataplexy, which is the sudden and brief loss of muscle strength or tone brought on by certain emotions or situations, sleep paralysis, vivid hallucinations when falling asleep or waking up, and disturbed nighttime sleep. 3,4 Narcolepsy is estimated to be severely underdiagnosed. 5,6 It can take an average of 10 years for people living with narcolepsy to be diagnosed after experiencing their first symptoms. 5 Narcolepsy can disrupt everyday life, 1 but the symptoms of narcolepsy aren’t always obvious, and may be inaccurately attributed to other medical conditions. 3,7 Getting to know narcolepsy means recognizing the symptoms, understanding their impact, and finding resources and support to help manage the disorder. Dr. Michael J. Thorpy, a world-renowned sleep specialist and narcolepsy expert based in New York, New York, and Jessica, a person living with narcolepsy, conducted a nationwide media tour in conjunction with Your Update TV and Harmony Biosciences to help address misconceptions, learn more about the signs and symptoms, find out what it is like to live with narcolepsy, and discover resources to help those impacted. For more information visit: WWW.KNOWNARCOLEPSY.COM and WWW.KNOWNARCOLEPSY.COM/STORIES References: 1 National Institutes of Health. Narcolepsy. U.S. Department of Health and Human Services. May 2017. 2 Narcolepsy Fact Sheet. NIH Publication No. 17-1637. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Narcolepsy-Fact-Sheet. 3 American Academy of Sleep Medicine. International Classification of Sleep Disorders. 3rd ed.; 2014. 4 Silber MH, Krahn LE, Olson EJ, Pankratz VS. The epidemiology of narcolepsy in Olmsted County, Minnesota: a population-based study. Sleep. 2002;25(2):197-202. 5 Overeem, Sebastiaan & Reading, Paul & Bassetti, Claudio. (2012). Narcolepsy. Sleep Medicine Clinics. 7. 263–281. 10.1016/j.jsmc.2012.03.013. 6 Carter LP, Acebo C, Kim A. Patients' journeys to a narcolepsy diagnosis: a physician survey and retrospective chart review. Postgrad Med. 2014;126(3):216-224. 7 Thorpy M, Morse AM. Reducing the clinical and socioeconomic burden of narcolepsy by earlier diagnosis and effective treatment. Sleep Med Clin. 2017;12(1):61-71. About YourUpdateTV: YourUpdateTV i s a social media video portal for organizations to share their content. It includes separate channels for Health and Wellness, Lifestyle, Media and Entertainment, Money and Finance, Social Responsibility, Sports and Technology. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

October 15, 2021 03:00 PM Eastern Daylight Time

Video

MCR Labs Announces First Annual “Cannabis Science Fair,” Begins Accepting Submissions

MCR Labs

Massachusetts-based cannabis testing company MCR Labs will host its inaugural “Cannabis Science Fair” at The BUild Lab IDG Capital Student Innovation Center on December 11. MCR Labs is partnering with The Cannabis Center of Excellence (CCoE) and Innovate@BU to organize the event, which is billed as “an exhibition of research and progress from the institutions working to expand our cannabis knowledge.” Groups interested in showcasing their cannabis-focused work at the science fair are invited to submit abstracts and other materials to MCR Labs via https://ma.mcrlabs.com/event/the-cannabis-science-fair. “We’re extremely excited about the potential for this event,” said Melissa Kenton, MCR Labs event and outreach coordinator. “It’s been on our radar for over a year, and we cannot wait to see what our fellow cannabis scientists and innovators are ready to share with us and the community.” Submissions for the Cannabis Science Fair will be assessed by MCR Labs and their event partners and selected for inclusion based on the soundness of methodologies, their potential scientific or industry impact and how thoroughly their findings are presented. A limited number of submissions will be selected for full presentations, poster presentations and demonstrations of any devices or prototypes. Projects chosen to be exhibited at the Cannabis Science Fair and other details about the event will be announced in November. Sponsorship opportunities are available and the event will be free to the public. Please contact MCR Labs for additional information about the event and how to join. About MCR Labs: MCR Labs is one of the longest operational cannabis testing laboratories on the East coast with facilities operating in several legal cannabis markets. We are ISO/IEC 17025:2017 accredited providers of analytical cannabis product testing and R&D services committed to assisting licensed marijuana establishments, patients, researchers, entrepreneurs, and advocates. Our team of chemists and pharmaceutical scientists are dedicated to advancing public health and safety through leading-edge chemical analysis of cannabis products and offering unparalleled guidance and support for partners, regulators, and the communities we serve. For more information visit http://mcrlabs.com. Contact Details MCR Labs Joe Crinkley +1 857-230-0839 joe@mcrlabs.com Company Website http://mcrlabs.com

October 14, 2021 02:17 PM Eastern Daylight Time

Image

GRYT Health and Bristol Myers Squibb Team Up to Launch Diversity in Oncology Initiative

GRYT Health

In light of the health disparities in oncology, GRYT Health (“grit”), an oncology solutions company that was started and run by cancer survivors, and Bristol Myers Squibb, have partnered to launch Diversity in Oncology, a virtual platform available at www.diversityinoncology.com to highlight and raise awareness of the health disparities in oncology facing diverse patients in the U.S. As one example of a racial disparity that exists in oncology, according to the National Institute of Health, “The invasive breast cancer age-adjusted mortality rate for black women age <40 was twice that for white women.” The Diversity in Oncology initiative will co-create a series of live, interactive sessions that bring together a multi-stakeholder audience of local and national organizations, patients and caregivers, healthcare providers, clinical trial teams and principal investigators, schools of public health and others. The goal of the initiative is to have courageous conversations about what’s currently inequitable, so that this cross-stakeholder, cross-cultural initiative can work towards structural changes in clinical trials. By bringing together diverse patients who have experienced inequities, alongside those who run trials, we will highlight current inequities and identify ways to adapt the system. The first of four live sessions will be October 27, 2021, from 4:00 – 5:30pm ET and is titled “Experience of Diverse Patients and Families in Clinical Trials.” It will feature an opening keynote from Wendy Short Bartie, senior vice president, U.S. Oncology at Bristol Myers Squibb, followed by a panel conversation moderated by Megan-Claire Chase, partnership director at GRYT Health and equity advocate. The session will include “break-out” rooms where attendees will be able to interact with the speakers to ask questions and to share their own stories and experiences in cancer clinical trials. “This initiative is about acknowledgment of the real and current issues in cancer clinical trials that need to be fixed,” said Megan-Claire Chase, partnership director at GRYT Health and moderator of the first session on the Diversity in Oncology platform. “This initiative is being developed with the voices of the underrepresented communities living these experiences, so that resources and structural change can be co-designed together.” The panel speakers in the first session will share their own personal experiences - as patients participating in clinical trials, as well as those who chose not to participate in a clinical trial. “When I participated in a clinical trial for breast cancer, the research team never showed any care or concern to my questions,” said Venus Ginés, president and founder, Día de la Mujer Latina® Inc. and speaker on the Oct. 27 session of Diversity in Oncology. “When I shared about the side effects that I was struggling with - they would say ‘I will document it on your file,’ but there was no support or follow-up care. After three months, I left the trial and upon not getting a call-back, I felt it had been a waste of my time.” Venus founded Día de la Mujer Latina® Inc. not only to educate Latinas about breast and cervical cancer, but as a result of her experience. In her work, she teaches promotores/community health workers to be more patient-centered and respectful to their constituents and patients, providing timely responses, resources, and support. Upcoming sessions, all available on the same virtual platform, will focus on topics relevant to bringing awareness to and developing solutions for healthcare inequities, including the experience of diverse physicians, principal investigators in clinical research, improving representation of diversity in clinical trials, and new models of academia and community collaboration in terms of clinical research. The virtual platform will provide resources and access to organizations and individuals advancing health equity, as well as the opportunity to participate in the live, interactive sessions to foster discussion and collaboration. To register for free access to the platform and the series, visit www.DiversityinOncology.com. All sessions will be recorded and also available on demand. Source: Breast cancer epidemiology in blacks and whites: disparities in incidence, mortality, survival rates and histology (nih.gov) GRYT Health is a digital oncology company that empowers people to be in charge of their own health through education, engagement and support. We offer a community free from judgment that focuses on humanity and the value each person brings. Our mission is to improve quality of life and increase survival for people facing cancer through the relentless focus on patient experience. We put patients first and work with healthcare organizations that do the same. We use the patient voice to enhance drug development and access; and together, we are helping to move healthcare forward. Visit www.grythealth.com or www.solutions.grythealth.com to learn more. Contact Details Lindsay Barnes +1 215-410-9982 Lindsay.Barnes@evokegroup.com Company Website https://www.grythealth.com

October 14, 2021 11:52 AM Eastern Daylight Time

Image

Cepheid recibe el marcado CE para Xpert Xpress CoV-2/Flu/RSV plus

Cepheid

Cepheid anunció hoy que ha recibido el marcado CE para el ensayo Xpert Xpress CoV-2/Flu/RSV plus, una prueba de diagnóstico molecular rápido para la detección cualitativa de los virus que causan la COVID-19, la gripe A, la gripe B y el virus respiratorio sincitial (RSV) en una muestra única de paciente. La nueva versión plus de la prueba proporciona una tercera diana génica para la detección del virus SARS-CoV-2 con el fin de afrontar el problema de futuras mutaciones del virus. Xpert Xpress CoV-2/Flu/RSV plus está diseñada para utilizarse en cualquiera de los más de 35 000 sistemas GeneXpert ® de Cepheid existentes en todo el mundo y proporcionar resultados en aproximadamente 36 minutos. Durante la pandemia, en el mundo se han documentado diversas variantes del virus que causa la COVID-19. Los virus cambian constantemente mediante mutación, y con el tiempo se espera que aparezcan nuevas variantes. La adición de una 3ª diana génica a la versión plus de la prueba CoV-2/Flu/RSV de Cepheid proporciona una cobertura más amplia para mitigar los posibles efectos de las futuras variaciones genéticas del virus. «En esta temporada de enfermedades respiratorias, el personal sanitario puede enfrentarse a diversas infecciones víricas que cursan con síntomas similares a los de la COVID-19, como la gripe A y B, y el virus respiratorio sincitial. Disponer de una prueba rápida y precisa, diseñada para detectar las variantes actuales y futuras de los virus que causan la COVID-19 y la gripe será cada vez más importante», afirmó el Dr. David Persing, MD, Ph.D., Director médico y tecnológico de Cepheid. «La posibilidad de recoger una muestra y realizar una única prueba multiplex de alta sensibilidad que detecte y distinga los cuatro virus proporcionará resultados prácticos para tomar mejores decisiones en primera línea en nuestros sistemas sanitarios». Se espera que esta semana se empiece a enviar ya la prueba Xpert Xpress CoV-2/Flu/RSV plus a los países que acepten productos con marcado CE. Visite https://www.cepheid.com/en para obtener más información, vídeos y prospectos. Para consultas a Cepheid, relacionadas con los medios de comunicación, contacte con: Darwa Peterson darwa.peterson@cepheid.com Acerca de Cepheid Cepheid, con sede en Sunnyvale, Calif., Cepheid es una empresa líder en diagnóstico molecular. Cepheid tiene el compromiso de mejorar la atención sanitaria mediante el desarrollo, la fabricación y la comercialización de sistemas y pruebas moleculares precisos y fáciles de utilizar. Con la automatización de procesos manuales sumamente complejos y laboriosos, las soluciones de la empresa ofrecen a las instituciones de cualquier tamaño una mejor manera de realizar pruebas de diagnóstico molecular sofisticadas para la detección de microorganismos y enfermedades genéticas. Aprovechando sus extensas capacidades en biología molecular, el trabajo de la empresa se centra en aquellas aplicaciones en las que más se necesitan resultados precisos, rápidos y fiables, como el control de las enfermedades infecciosas y el cáncer. Para obtener más información, visite http://www.cepheid.com. Contact Details kdm communcations Sarah Khan +44 1480 405333 sarahk@kdm-communications.com Company Website https://www.cepheid.com/en

October 14, 2021 08:10 AM Eastern Daylight Time

Image

KOAN CORDIALS ARE NOW AVAILABLE FOR DELIVERY THROUGHOUT CALIFORNIA

Resonate Blends, Inc

Koan, a Resonate Blends brand, is leading a new area of plant-based wellness with the direct-to-consumer launch of the world’s first cannabis cordials - non-alcoholic, single-dose, plant-derived liquids designed to help mindful consumers to find inspiration, restore balance, and improve the quality of their lives. By combining the wisdom of traditional, holistic wellness practices with cutting-edge science and technology, Koan has developed a brand-new way to harness the wide-ranging benefits of cannabis, utilizing various ratios of THC and CBD, along with botanical terpenes, adaptogens, and other plant extracts to deliver precise and consistent life-enhancing experiences. The six cordials - Calm, Balance, Play, Create, Delight, and Wonder – have the fast on-set of a tincture, the long duration of an edible, and the ease and social benefits of a beverage all in one single-dose bottle. Calm, for example, has a large concentration of CBD with low levels of THC ensuring a profoundly calming experience without getting you high. The low level of THC amplifies the benefits of natural plant extracts including Linalool—known to help treat anxiety, depression, and insomnia—Beta-Caryophyllene, an anti-inflammatory, and Limonene—a naturally-derived anti-depressive—to help ease stress and return to a comfortable and functional mind/body state. On the other extreme is Koan's Wonder formulation carefully crafted to support consumers in every way when their goal is to ponder the infinite. Wonder has higher levels of THC with low levels to CBD designed to help refine the powerful experience. Koan's other blends of Cordials enhance creativity, bring a feeling of enchantment, or unleash a feeling of energy, joy, and more. The full range of products is designed to help those using cannabis in an intentional way to find what they are looking for with precision, consistency, and refinement. “At Koan we’re mastering the art of experience. It’s more than science, it’s our passion - refining, amplifying, and calibrating cannabis so you can always find what you are looking for. We are deeply enmeshed in the science, we have two patents pending supporting our formulations, processes, and bioavailability to ensure that consumers get exactly what they expect, every time, from our products,” said Geoff Selzer, CEO and Founder. “We are delighted to partner with Grassdoor for our direct to home delivery ensuring that all of our customers can get our products whenever they choose in the most convenient, safe, discrete, and reliable fashion possible.” Koan is committed to demystifying cannabis and harnessing its impactful ingredients to create products that support intentional and mindful use as a core part of daily wellness—physical, spiritual, and most importantly, emotional. Through precision crafting, Koan invites a general sense of well-being, lean-in awareness and presence rather than the “check-out high” normally associated with most cannabis-based products. The single-dose cordials are artfully designed to be both portable and discrete, with fast-acting ingredients that allow a quick onset for a long-lasting experience of up to four hours. The delightful citrus and botanical notes of the cordials can be enjoyed directly out of the bottle or poured into any beverage or one of Koan’s signature cannabis cocktail recipes. Koan Cordials are now available for purchase directly at https://koan.life. Koan provides the option to order individual cordial three packs, or in themed bundles such as the Serenity Bundle, Engage Bundle, or the Experience Bundle. Koan has proudly partnered with Grassdoor, the premier direct-to-consumer e-commerce solution for cannabis brands in California, to allow consumers to shop Koan’s portfolio of Cordials with same-day delivery across Southern California (including Los Angeles and San Diego) and Northern California (including San Francisco, San Jose, and Oakland). Grassdoor is one of the largest end-to-end delivery solutions in cannabis, providing same-day delivery to 75% of the population of California. ABOUT RESONATE BLENDS, INC. Resonate Blends, Inc. (OTCQB:KOAN) develops Koan Cordials, meticulously formulated blends of THC, CBD, Terpenes, and Botanicals that provide a refined cannabis experience. Unlike strain-based or full-spectrum products, Koan Cordials are scientifically crafted to highlight specific cannabis characteristics, with predictable experiences and intensity allowing people to tap into specific feelings in a new, better way. ABOUT GRASSDOOR Grassdoor is the premier delivery marketplace and direct-to-consumer ecommerce platform in cannabis, providing customers same-day delivery of top brands in 45 minutes or less throughout California, including Los Angeles, Orange County, San Diego, Ventura, San Francisco, San Jose, Oakland, and more. In addition to being the fastest licensed delivery service in the state, Grassdoor aims to be the safest, friendliest, and most reliable cannabis delivery solution worldwide. This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Examples of forward-looking statements include, among others, statements we make regarding guidance relating to net income; anticipated customer onboardings; and expected operating results, such as revenue growth and earnings. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set out in the Company's SEC filings. These risks and uncertainties could cause the Company's actual results to differ materially from those indicated in the forward-looking statements. Contact Details BPCM Katie Bell +1 323-655-5541 koancordials@bpcm.com Company Website https://www.resonateblends.com

October 13, 2021 08:03 AM Pacific Daylight Time

Healthcare

ALLIED CORP SIGNS MAJOR SUPPLY AGREEMENT WITH US MULTI STATE OPERATOR (MSO) AND SALES AGREE-MENT FOR ALLIED’S CBD BRANDS

Pediatric Lyme Disease—'An Epidemic Within a Pandemic!’—to be Focus of Free Webinar Hosted by Quidel Corporation Oct. 21

Ultrahuman hires former KKR exec ahead of expansion drive

The U.S. Chamber Discover & Deliver Initiative Spotlights Medical Innovation Happening across Main Street America

Living With Narcolepsy: Symptoms and Misconceptions

MCR Labs Announces First Annual “Cannabis Science Fair,” Begins Accepting Submissions

GRYT Health and Bristol Myers Squibb Team Up to Launch Diversity in Oncology Initiative

Cepheid recibe el marcado CE para Xpert Xpress CoV-2/Flu/RSV plus

KOAN CORDIALS ARE NOW AVAILABLE FOR DELIVERY THROUGHOUT CALIFORNIA